726 Establishing proof of mechanism in patients: preliminary biomarker data of SRK-181 (a latent TGFβ1 inhibitor) from DRAGON Study

• Minal Barve,
• Ahmad A Tarhini,
• Deepak Kilari,
• Randy Sweis,
• Timothy Yap,
• John Clark,
• Justin Gainor,
• Lu Gan,
• Ulka N Vaishampayan,
• Amna Sher,
• Yawen Ju,
• Susan Henry,
• Stephen DeWall,
• Asia McCune,
• Mo Qatanani

Affiliations

Minal Barve

3Mary Crowley Cancer Research Center, Dallas, TX, USA

Ahmad A Tarhini

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Deepak Kilari

5Medical College of Wisconsin, Milwaukee, WI, USA

Randy Sweis

8University of Chicago, Chicago, IL, USA

Timothy Yap

7The University of Texas, Houston, TX, USA

John Clark

Australian Council on Healthcare Standards, Sydney, Australia

Justin Gainor

6Massachusetts General Hospital, Boston, MA, USA

Lu Gan

1Scholar Rock, Cambridge, MA, USA

Ulka N Vaishampayan

8Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA

Amna Sher

9Stony Brook University, Stony Brook, NY, USA

Yawen Ju

13Scholar Rock, Inc., Cambridge, MA, USA

Susan Henry

13Scholar Rock, Inc., Cambridge, MA, USA

Stephen DeWall

1Scholar Rock, Inc., Cambridge, MA, USA

Asia McCune

1Scholar Rock, Inc., Cambridge, MA, USA

Mo Qatanani

1Scholar Rock, Inc., Cambridge, MA, USA